Cytek Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
CTKB$5.79-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive (Loss) Income
| Three months ended September 30, | Nine months ended September 30, | |||
|---|---|---|---|---|
| (In thousands, except share and per share data) | 2025 | 2024 | 2025 | 2024 |
| Revenue, net: | ||||
| Product | $38,114 | $39,544 | $97,639 | $108,242 |
| Service | 14,179 | 11,956 | 41,713 | 34,735 |
| Total revenue, net | 52,293 | 51,500 | 139,352 | 142,977 |
| Cost of sales: | ||||
| Product | 17,728 | 17,490 | 48,178 | 50,044 |
| Service | 7,014 | 5,005 | 19,599 | 15,479 |
| Total cost of sales | 24,742 | 22,495 | 67,777 | 65,523 |
| Gross profit | 27,551 | 29,005 | 71,575 | 77,454 |
| Operating expenses: | ||||
| Research and development | 8,956 | 9,882 | 27,506 | 29,679 |
| Sales and marketing | 11,666 | 12,429 | 36,309 | 37,240 |
| General and administrative | 16,121 | 10,942 | 42,550 | 34,044 |
| Total operating expenses | 36,743 | 33,253 | 106,365 | 100,963 |
| Loss from operations | (9,192) | (4,248) | (34,790) | (23,509) |
| Other income (expense): | ||||
| Interest expense | (494) | (119) | (1,199) | (694) |
| Interest income | 573 | 1,433 | 1,636 | 4,208 |
| Other income, net | 1,344 | 3,091 | 8,543 | 3,972 |
| Total other income, net | 1,423 | 4,405 | 8,980 | 7,486 |
| (Loss) income before income taxes | (7,769) | 157 | (25,810) | (16,023) |
| Benefit from income taxes | (2,291) | (784) | $(3,347) | (360) |
| Net (loss) income | $(5,478) | $941 | $(22,463) | $(15,663) |
| Net (loss) income, basic and diluted | $(5,478) | $941 | $(22,463) | $(15,663) |
| Net (loss) income per share, basic | $(0.04) | $0.01 | $(0.18) | $(0.12) |
| Net (loss) income per share, diluted | $(0.04) | $0.01 | $(0.18) | $(0.12) |
| Weighted-average shares used in calculating net (loss) income per share, basic | 127,547,859 | 131,003,744 | $127,604,317 | $131,121,301 |
| Weighted-average shares used in calculating net (loss) income per share, diluted | 127,547,859 | 132,785,552 | $127,604,317 | $131,121,301 |
| Comprehensive (loss) income: | ||||
| Net (loss) income | $(5,478) | $941 | $(22,463) | $(15,663) |
| Foreign currency translation adjustment, net of tax | 741 | 101 | $784 | 1,232 |
| Unrealized gain on marketable securities | 118 | 195 | $20 | 144 |
| Net comprehensive (loss) income | $(4,619) | $1,237 | $(21,659) | $(14,287) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.